Pfizer Approved by the Ministry of Food and Drug Safety for COVID-19 Variant Vaccine in the 2025-2026 Season...Signing a contract with HKINOEN to promote the national vaccination project
Sep 04, 2025
|
On the 29th of last month, the Ministry of Food and Drug Safety approved the newly approved Cominati LPIE One Freefield Syringe (Sars Coronavirus-2 mRNA vaccine, photo)' as an indication for the prevention of COVID-19 caused by the SARS-CoV-2 virus in people over 12 years of age. The targeted LP.8.1 variant is a JN.1 family subvariant. The LP.8.1 variant was designated as a monitoring variant (VUM) by the World Health Organization (WHO) in January this year, and the World Health Organization (WHO), the European Medicines Agency (EMA), and the U.S. Food and Drug Administration (FDA) recommended the use of vaccines for the strain. The new vaccine will administer 0.3 mL as an intramuscular injection, regardless of previous COVID-19 vaccination, and should be administered at least three months after the last vaccination date if previously vaccinated against COVID-19.
Song Chan-woo, Vice President of primary care division at Pfizer Pharmaceuticals Korea, said "After the end of the pandemic, interest or concern about COVID-19 has significantly decreased, but COVID-19 continues to mutate and cause patients."With this authorization, we will continue to supply stable vaccines under close cooperation with the government to contribute to the protection of high-risk groups in Korea and the improvement of public health, as the COVID-19 vaccine has been officially introduced into the National Vaccination Project (NIP)."
|
Last year, HKINOEN was in charge of distributing CominatiJN Wonju (single-use) (Bretobameran) (Sas Coronavirus-2 mRNA vaccine) to the private market, and recently, it is in charge of distributing national vaccination projects for high-risk groups (aged 65 and older, immunocompromised people) worth about 200 billion won. Through the signing of the COPromotion contract, HKINON and Pfizer Pharmaceutical Korea will strengthen cooperation in the areas of promotions subject to the national vaccination project.
Kwak Dal-won, CEO of HKINOEN, said "It is meaningful to expand the corporate promotion contract for the national vaccination project following the distribution of private and national vaccination projects."Our sales?"Based on its distribution capacity, it will contribute to the stable supply of 'Cominati®LPATE One Freefield Syringe' and to the improvement of public health.'
Oh Dong-wook, CEO of Pfizer Pharmaceuticals, Korea, said "We are meaningful to expand the scope of cooperation to HKINOEN with abundant experience and expertise in vaccine distribution to distribution and copromotion of the national vaccination business."Korean Pfizer Pharmaceutical will continue to make efforts to contribute to the protection of high-risk groups, especially those aged 65 or older and immunocompromised, through the stable supply of COVID-19 vaccines and realize "innovation that changes the lives of patients"" he said.
This article was translated by Naver AI translator.
